Varicella-zoster virus (VZV) specifies the synthesis of at least four families of glycoproteins, which have been designated gpl, gpII, gpIII, and gpIV. In this report we describe the assembly and processing of VZV gpII, a structural protein of an apparent Mr of 140,000, which is the homolog of gB of herpes simplex virus. For these studies, we used two anti-gpII monoclonal antibodies which exhibited both complement-independent neutralization activity and inhibition of virus-induced cell-to-cell fusion. Pulse-chase labeling experiments identified a 124,000-Mr intermediate which was chased to the mature 140,000-Mr product when analyzed in nonreducing gels; in the presence of a reducing agent, the native gpl40 was cleaved into two closely migrating species (gp66 and gp68). The biosynthesis of VZV gpII was further analyzed in the presence of the following inhibitors of glycoprotein processing: tunicamycin, monensin, castanospermine, swainsonine, and deoxymannojirimycin. All intermediate and mature forms were digested with endoglycosidases H and F, neuraminidase, and 0-glycanase to further define high-mannose, complex, and 0-linked glycans. Finally, the addition of sulfate residues was investigated. This characterization of VZV gpII revealed the following results. (i) gp128 and gp124 were early high-mannose forms, (ii) gp126 was an intermediate form with complex N-linked oligosaccharides, (iii) gp130 was a later intermediate with both N-linked and 0-linked glycans, and (iv) the mature product gpl40 contained a mixture of N-linked and 0-linked glycans which were both sialated and sulfated. Further investigations indicated that gpII sulfation was inhibited by tunicamycin and castanospermine but not by deoxymannojirimycin or swainsonine. We also concluded that VZV gpII displayed many biological and biochemical properties similar to those of its herpes simplex virus homolog gB.
The genome of varicella-zoster virus (VZV) encodes at least four families of glycoproteins. As with other herpesviruses, the glycosylated products are found in both the enveloped virion and the membrane of the VZV-infected cell (for a review, see reference 15a). In previous studies from several laboratories, these glycoproteins were designated by different classification schemes. To avoid further confusion, a consensus was reached on a common nomenclature for the VZV glycoproteins, based on a Roman numeral designation, with priority determined by the date of identification of the corresponding structural gene (3) . The classification document contains a listing of all prior publications relating to the identification of VZV glycoproteins. Since gp98 (98 x 103; also called VZV gC) was the first viral glycoprotein to be genetically mapped (12) , it was assigned the first numeral, VZV gpl. Based on preliminary genetic data, gp140 and gpll8 were designated gpII and gpIII, respectively. A fourth glycoprotein has now been identified, whereas the fifth remains a hypothetical gene (4, 5) .
This report describes biological properties and biochemical analyses of VZV gpII. The disulfide-linked glycoprotein was first identified by our laboratory in 1984, on the basis of immunoreactivity profiles of two murine monoclonal antibodies (17) . Both of these antibodies precipitate two fucosylated species (a minor gp124 and a prominent gp66) under reducing conditions; when the same reaction is carried out in the absence of 2-mercaptoethanol, only one prominent fucosylated protein is observed at 140,000 Mr. The same phe-* Corresponding author.
nomenon is apparent when a preparation of purified virions is analyzed; under reducing conditions, a lower-molecularweight [3Hjfucose-labeled protein (gp66) is detected in the fractionated polypeptide profile, whereas under nonreducing conditions, gp66 is replaced by a band at 140,000 Mr. Antibodies to this disulfide-linked glycoprotein complex appear in the sera of children shortly after primary VZV infection (chicken pox) (17, 37) . Therefore, this viral glycoprotein appears to be an immunodominant species in the humoral immune response to naturally acquired disease. The structural gene which encodes VZV gpII has been mapped by hybrid selection and in vitro translation to the HinidIII D fragment near the center of the UL genomic region (22) . In this paper, we characterize, in detail, the glycomoieties and the processing steps associated with the assembly of this glycoprotein, which is the homolog of herpes simplex virus (HSV) glycoprotein gB (4) . For these experiments, we have used several newly discovered inhibitors of glycoprotein processing events. One important outcome of this investigation is the demonstration that a neutralization epitope is detectable in an early high-mannose form of VZV gpII.
MATERIALS AND METHODS
Cells and virus. The Mewo strain of human melanoma cells (HMC) was (15, 28) . To study sulfation, VZV-infected monolayers were incubated for 36 h in MEM-FBS supplemented with 0.5 mCi of 35S04 per ml (specific activity, 25 to 40 Ci/mg). Cell monolayers were harvested by the addition of either 2.5 (for 75-cm2 monolayers) or 1 ml (for 25-cm2 monolayers) of RIPA buffer (0.15 M NaCl, 0.05 M Tris buffer, pH 7.4. containing 1% Nonidet P-40, 1% deoxycholate, and 0.1% sodium dodecyl sulfate [SDS] ). Radioimmune precipitation and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) were carried out by previously described methods (16, 17) . In some experiments, we precipitated viral glycoproteins with biotinylated monoclonal antibody and streptavidin-agarose (D. R. Gretch, M. Suter, and M. F. Stinski, Anal. Biochem., in press). The apparent molecular weights of the precursor glycoproteins were estimated by their migration in SDS-PAGE compared with known-molecular-weight marker proteins, with the knowledge that this method may yield an apparent M, for glycoproteins which is different from the true M,.
Neutralization assay and fusion inhibition experiments. The plaque reduction technique to quantitate neutralization activity has been previously described in detail (16) . For fusion inhibition experiments, HMC monolayers grown on 8-well Lab-Tek tissue culture slides (Miles Scientific, Div. Miles Laboratories, Inc., Naperville, Ill.) were inoculated with 100,000 trypsin-dispersed VZV-infected cells. Ascites-fluid antibody (total protein, 35 mg/ml; diluted 1:10 and 1: 1,000 in MEM-FBS) was added at 2, 4, 12, and 24 h postinfection. At 48 h postinfection, cell monolayers were fixed for 30 min in 0.15 M NaCI-Formalin (9:1, vol/vol) and air dried; then the monolayers were stained by being submerged in diluted Wright-Giemsa stain for 45 min.
Digestion with glycosidases. Methods for digestion of VZV glycoproteins with endo-beta-N-acetylglucosaminidase H (Endo H), endo-beta-N-acetylglucosaminidase F (Endo F), endo-alpha-N-acetylgalactosaminidase (O-glycanase), and neuraminidase have been previously described (28, 30 (36) . Some of the biologically important functions ascribed to these molecules include (i) attachment to cell surface, (ii) penetration into host cell, and (iii) induction of cell-to-cell fusion. To ascertain a possible role for VZV gpIl, we first tested our two previously described anti-gpIl monoclonal antibodies (17) for their ability to inhibit plaque formation in VZV-infected cell monolayers. In these assays, cell-free virus and antibody were first mixed together, allowed to react, and then added to an uninfected HMC monolayer (16) . Each of the two monoclonal antibodies (clones 151 and 158) was capable of reducing VZV plaque formation by greater than 50% when tested at a dilution of 1:10,000. These titers were unchanged by the addition of guinea pig serum as a source of complement.
In addition to our neutralization assays, we also tested our panel of antibodies for their ability to inhibit the syncytial formation which is characteristic of VZV cytopathology in an in vitro system. In contrast to the neutralization experiments, cell monolayers were first infected with virus before exposure to antibody. Diluted (1:10 or 1:1,000) ascites monoclonal antibody was added to infected monolayers at various times postinfection and then allowed to react until a rating from 3 to 4+ for VZV cytopathology was observed in untreated control wells. The photographs shown in Fig. 1 (17) . Effect of inhibitors of glycoprotein processing on gpII biosynthesis. We have examined the effect of three inhibitors of glycoprotein processing on the formation of mature gplI.
The inhibitors included swainsonine, castanospermine, and deoxymannojirimycin. These inhibitors prevent the formation of N-linked complex glycans, by interfering with various trimming and processing events (9) . In particular, swainsonine inhibits Golgi mannosidase 11 (10) , whereas deoxymannojirimycin and castanospermine exert at least part of their effect on mannosidase 1 and glucosidase 1, respectively (11, 32) . In addition to the above inhibitors, we also investigated the effects of the antibiotic tunicamycin and the ionophore monensin on the biosynthesis and processing of VZV gpII (9, 26) .
For these experiments, monolayers of infected cells were grown in the presence of an inhibitor and then radiolabeled as described in Materials and Methods. The cultures were harvested, solubilized with detergents, and analyzed by immunoprecipitation reactions. Fig. 3 is an example of our findings under nonreduced conditions. Lane 1 contained
[3H]fucose-labeled antigen. Lane 2 contained untreated r35S]methionine-labeled glycoproteins precipitated by antibody 151; the locations of the two major bands gpII(140) and gp124 are designated in the right-hand margin. In contrast to lanes 1 and 2, no proteins were visible in the immunoprecipitate of the tunicamycin-treated sample shown in lane 3. Since tunicamycin inhibits all N-linked glycosylation reactions, monoclonal antibody 151 probably bound poorly, if at all, to the nonglycosylated precursor of gpII. Alternatively, since nonglycosylated analogs of glycoproteins may be more susceptible to intracellular proteases (26) . the altered gpII products synthesized in the presence of tunicamycin may be degraded and thus undetectable in these experiments. These negative findings reaffirmed similar negative results in the pulse-chase labeling experiments (Fig. 2) .
The effects of castanospermine and swainsonine on glycoprotein biosynthesis are displayed in the profiles in Fig. 3 , lanes 4 and 5. After a castanospermine block, gp124 was replaced by a more slowly migrating product (M,-128.000), while the major product migrated slightly faster than did gpl40 in the control lane. The effect of swainsonine was an even more subtle event, viz., only a slight decrease in the apparent molecular weight of the major component (gpl40) was observed. Likewise, the deoxymannojirimycin block minimally altered the electrophoretic mobility of forms gpl40 and gp124 (lane 5) . By comparison, monensin exerted a more dramatic effect (lane F); formation of the mature gpl40 was completely blocked. In its place was a 135,000-Mr form, as well as gp124. The relative amount of the A .
. 135,000-Mr product was dependent upon the completeness of the monensin block, i.e., with higher concentrations of the ionophore, there was a greater accumulation of gp124 and less of the higher-molecular-weight product (data not shown).
Another side effect of growth of the viral glycoprotein in the presence of inhibitors of glycoprotein processing was demonstrable (Fig. 3, lanes 5 and 6) . Both deoxymannojirimycin and swainsonine blocks led to increased amounts of cleavage of the native gpl40, with the appearance of two products at approximately 60,000 daltons. These lower-molecular-weight proteins were virtually never seen under the usual conditions of glycoprotein biosynthesis, as analyzed in nonreducing gels (Fig. 3, lane 2; Fig. 2 , lanes 5 to 7); nor were the 60,000-Mr products seen in VZV-infected cultures treated with either castanospermine or monensin (Fig. 3, lanes 4 and 7) , which inhibit different stages of glycoprotein biosynthesis. Digestion of gpl4O with Endo H and Endo F. After determining that gpl40 was a disulfide-linked mature glycoprotein, structural analyses of the glycoprotein and the individual subunits were performed. We began by examining the susceptibility of gpl40 to two endoglycosidases which cleave corresponding to a loss of approximately 3.000 daltons (Fig.  4) . Treatment of the intermediate gp124 with the same endoglycosidase led to an even greater change in molecular weight; a new band of approximately 100,000-M,. was found immediately above the location of gpl(98). The lOOK protein corresponded in molecular weight to the polypeptide backbone, as estimated from the DNA sequence of the glycoprotein gene (4).
When the glycoproteins in the castanospermine-and swainsonine-treated cultures were subjected to similar treatment, the shift in electrophoretic mobility of the final products in lanes 4 to 7 appeared to be slightly greater than in the untreated cultures (Fig. 4, lanes 2 to 3) . This finding is to be expected since the two inhibitors prevent formation of complex-type glycans, which are Endo H resistant. Likewise, the decrease in molecular weight of the 128,000-M,- 10) . The same digestions were also performed on the reduced products of gpll. During this series of experiments, we observed a previously unappreciated glycoprotein species. That is, we recognized that the gp124 band actually consisted of two closely migrating glycoproteins which we have now redesignated gp124 and gp126 (Fig. 6) . The larger of the two species (gpl26) was fucosylated (17) and most likely represented a further processed form of gp124. Since fucosylation and sialation occur late in glycoprotein processing, gp126 was also examined for the presence of sialic acid. After incubation with neuraminidase. the upper band disappeared and the lower band (gp124) increased in intensity (lane 3). These results indicated the gp126 was sialated and. therefore, contained complex-type glycans (25) . Upon the addition of neuraminidase to the two lower-molecularweight forms, both decreased slightly in size (lane 3). Subsequent treatment with O-glycanase caused a marked increase in mobility of gp68 (lane 4). The last result supported the positive findings after O-glycanase digestion of native gpl40 (Fig. 5) .
Sulfation of viral glycoproteins. Because of previous studies (18) which indicated that sulfation occurred on HSV glycoproteins including HSV gB, the homolog of VZV gpIl, we investigated whether this posttranslational modification was seen within VZV-specified glycoproteins. To this end, we added 35SO4 to culture medium overlying infected cultures, as well as to uninfected HMC monolayers. Very few sulfated forms were visible in uninfected cell cultures; however, in VZV-infected cells, it was evident that the predominant glycoprotein species gpl was highly sulfated, while lesser amounts of the isotope comigrated with gpII and gpIII (fluorogram not shown). To substantiate that the 35S-labeled band at 140,000 Mr was actually gpII, we prepared detergentsolubilized extracts for analysis by immunoprecipitation with monoclonal antibody 151. The immunoprecipitate contained 35S-labeled gpII (Fig. 7A, lane 2) . We also added 35 04 to VZV-infected cultures containing the previously described inhibitors of glycoprotein biosynthesis and processing (lanes 3 to 7). In the presence of tunicamycin or monensin, sulfation of gpII was markedly inhibited; likewise, sulfation was only minimally detectable after castanospermine block. However, addition of swainsonine or deoxymannojirimycin to the medium of infected cell cultures had little effect on subsequent sulfation of the final viral glycoprotein product.
Sulfation of the glycans of gpII was further analyzed by digestion with neuraminidase and O-glycanase. Treatment of the 35S-labeled glycoprotein with neuraminidase reduced the molecular weight in a manner similar to that described earlier in these Results (Fig. 7B) . Further treatment of desialated gpII by O-glycanase led to the loss of a detectable radioactive band. The last result suggested that an appreciable amount of sulfation occurred on 0-linked glycomoieties which were released by endo-alpha-N-acetylgalactosaminidase.
DISCUSSION
We have now studied the biosynthesis of the three major VZV glycoproteins: gpl(98), gpIII(118), and gpII(140). The predominant viral glycoprotein within the VZV-infected cell membrane is the phosphorylated species gpl (iSa, 29) . The backbone of this mature product is a 73,000-Mr polypeptide, to which both N-linked and 0-linked glycans are attached (30) . Since the final product is Endo H resistant, all of the N-linked oligosaccharides appear to be processed to complex chains. The least prominent viral glycoprotein in the infected-cell membrane is gpIII, an 118,000-Mr product which contains predominantly N-linked oligosaccharides of the complex type (28) . The high-mannose intermediate form of gpIII is a 94K product built upon a 79K backbone. Finally, gpII described herein has been the most difficult of the three major VZV glycoproteins to characterize because of its susceptibility to cleavage. Recent studies have shown that the imputed polypeptide backbone contains 868 amino acids; after glycosylation has been completed, the mature glycoprotein appears to be cleaved between amino acids 431 to 432, when placed under reducing conditions (4, 22) .
A schematic representation of the assembly and processing of VZV gpII(140) is shown in Fig. 8 . The molecular weight of the polypeptide backbone (approximately 100,000) was derived from the VZV genomic sequence data of Davison and Scott (4 represented high-mannose forms, which were sensitive to treatment with Endo H. The slightly heavier 12'6,000-Ml, product included some glycans which were fucosylated and sialated, i.e., probably a hybrid glycoprotein. The intermediate viral products were further processed by the addition of 0-linked glycans, several of which probably contained sialic acid and sulfate residues, to build a 140,000-Al, native product. This mature glycoprotein was subsequently cleaved into subunits of similar molecular weight (ca. 60,000). which were discernible after disruption of interchain disulfide bonds by 2-mercaptoethanol (17, 31) . Interestingly, only one of the two reduced forms was highly fucosylated. Another important aspect of this schema relates to the immunoprecipitability of the individual proteins. That the early high-mannose forms were recognized by the monoclonal antibody, while the precursor polypeptide was not. suggests that the formation of the neutralization epitope occurs shortly after the addition of mannose chains (gp128) and is not dependent on the later glycosylation events illustrated in Fig. 8 .
Sulfation of envelope glycoproteins has been reported in many RNA and DNA viruses (19. 33) . The major sulfated HSV glycoprotein is gE, whereas lesser degrees of sulfation are observed on gD, gB, and gC (18) . However, the effects of inhibitors of glycoprotein processing on sulfation have not been extensively investigated in a herpesvirus system (25) . (27) . This observation led the investigators to conclude that certain early processing steps. e.g., removal of glucose units from the high-mannose core. were required before sulfate groups could be attached to oligosaccharides. Thus, swainsonine and deoxymannojirimycin would not inhibit sulfation because they exert their effect after the glucosyl groups have ali-eady been trimmed. Since monensin also prevented sulfation. the location of the sulfotransferase must be distal to the monensin block within the Golgi apparatus. Although not further investigated in this study, we recently determined that another modification of viral glycoproteins, phosphorylation, does not occur on gpII. but appears to be restricted to VZV gpl (29) . With the availability of DNA sequence data on the human herpesvirus genomes, it is now apparent that varying degrees of homology can be found between the glycoproteins encoded by different herpesviruses (4) . In particular. VZV gpII is related to gpB of HSV types 1 and 2 (1, 2) . Antigenic similarities between these HSV and VZV glycoproteins had been postulated previously because of serologic crossreactivity detected in both polyclonal sera and monoclonal antibodies (8, 24, 34 (6, 36) . As shown in this paper and earlier reports (7, 38) . some monoclonal and polyclonal antibodies to VZV gpll also neutralize virus in the absence of exogenous complement, whereas other antigpll antibodies lack this capability (7. 13, 23). On the basis of studies of mutant HSV strains, HSV gB is thought to play an important role in virus penetration (36) . By analogy, the neutralization activity present in anti-gpll antibodies may reflect interference with VZV penetration of the cell. These comparisons are especially important for VZV investigations, because there are no well-defined mutant strains of this closely cell-associated herpesvirus. The two antibodies described in this report also inhibited VZV-induced cell-tocell fusion; however. they did not mediate antibodydependent cellular cytotoxicity of VZV-infected fibroblasts by human peripheral blood mononuclear cells (20) . Thus, the above observations in several different herpesvirus systems suggest an important role for this glycoprotein in both virus penetration of the cell and virus-induced cell-to-cell fusion. After VZV infection in the human host, therefore. the anti-gplI antibody which develops is most likely directed toward a complement-independent neutralization epitope on gpII (17. 37) . This humoral response. in turn, halts further spread of the viral agent.
